Charles River Laboratories Intl. (NYSE:CRL) and BIOQUAL (OTCMKTS:BIOQ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Insider & Institutional Ownership
96.2% of Charles River Laboratories Intl. shares are owned by institutional investors. 2.1% of Charles River Laboratories Intl. shares are owned by company insiders. Comparatively, 39.2% of BIOQUAL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Charles River Laboratories Intl. has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, BIOQUAL has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Charles River Laboratories Intl. and BIOQUAL, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories Intl.||0||6||9||0||2.60|
Charles River Laboratories Intl. currently has a consensus target price of $131.47, suggesting a potential downside of 3.80%. Given Charles River Laboratories Intl.’s higher probable upside, equities research analysts plainly believe Charles River Laboratories Intl. is more favorable than BIOQUAL.
BIOQUAL pays an annual dividend of $0.60 per share and has a dividend yield of 1.6%. Charles River Laboratories Intl. does not pay a dividend.
Earnings and Valuation
This table compares Charles River Laboratories Intl. and BIOQUAL’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories Intl.||$1.86 billion||3.58||$123.35 million||$5.27||26.25|
|BIOQUAL||$35.88 million||0.92||$3.66 million||N/A||N/A|
Charles River Laboratories Intl. has higher revenue and earnings than BIOQUAL.
This table compares Charles River Laboratories Intl. and BIOQUAL’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories Intl.||6.39%||25.08%||8.54%|
Charles River Laboratories Intl. beats BIOQUAL on 10 of the 13 factors compared between the two stocks.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Bioqual, Inc. provides research, development, consulting, and testing/assay services to commercial clients and government laboratories in the United States. The company provides research services in the areas of cancer, AIDS, hepatitis, influenza, immunology, transgenic, contraception, breeding and development of genetically defined animals, and neurobiology and behavior, as well as zika, dengue, malaria, respiratory syncytial virus, and other infectious diseases. Its services also include sample processing, virus stock generation, infectious virus quantitation, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides in-vivo animal model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.